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Background: There is little published guidance as to the sample size required for a pilot or feasibility trial despite
the fact that a sample size justification is a key element in the design of a trial. A sample size justification should
give the minimum number of participants needed in order to meet the objectives of the trial. This paper seeks to
describe the target sample sizes set for pilot and feasibility randomised controlled trials, currently running within
the United Kingdom.
Methods: Data were gathered from the United Kingdom Clinical Research Network (UKCRN) database using the
search terms ‘pilot’ and ‘feasibility’. From this search 513 studies were assessed for eligibility of which 79 met the
inclusion criteria. Where the data summary on the UKCRN Database was incomplete, data were also gathered from:
the International Standardised Randomised Controlled Trial Number (ISRCTN) register; the clinicaltrials.gov website
and the website of the funders. For 62 of the trials, it was necessary to contact members of the research team by
email to ensure completeness.
Results: Of the 79 trials analysed, 50 (63.3%) were labelled as pilot trials, 25 (31.6%) feasibility and 14 were
described as both pilot and feasibility trials. The majority had two arms (n = 68, 86.1%) and the two most common
endpoints were continuous (n = 45, 57.0%) and dichotomous (n = 31, 39.2%). Pilot trials were found to have a
smaller sample size per arm (median = 30, range = 8 to 114 participants) than feasibility trials (median = 36, range =
10 to 300 participants). By type of endpoint, across feasibility and pilot trials, the median sample size per arm was
36 (range = 10 to 300 participants) for trials with a dichotomous endpoint and 30 (range = 8 to 114 participants) for
trials with a continuous endpoint. Publicly funded pilot trials appear to be larger than industry funded pilot trials:
median sample sizes of 33 (range = 15 to 114 participants) and 25 (range = 8 to 100 participants) respectively.
Conclusion: All studies should have a sample size justification. Not all studies however need to have a sample size
calculation. For pilot and feasibility trials, while a sample size justification is important, a formal sample size
calculation may not be appropriate. The results in this paper describe the observed sample sizes in feasibility and
pilot randomised controlled trials on the UKCRN Database.
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The National Institute of Health Research Evaluation,
Trials and Studies Coordinating Centre (NETSCC) de-
fines a pilot trial for a randomised controlled trial (RCT)
as ‘a version of the main study…run in miniature to test
whether the components of the study can all work
together’ and a feasibility study for an RCT as ‘research
done before a main study to answer the question “Can
this study be done?”. [1] However, whilst some authors,
including Arain et al. [2] recommend these definitions,
in truth there is no consensus. Stallard [3] reports a rea-
son for this as being in part, due to the wide variety of
purposes for which pilot trials are undertaken.
Thabane et al. [4] give a number of reasons as to why
pilot trials may be conducted. They state that con-
ducting a pilot trial before a main study can increase the
likelihood that the main study will be a success, and may
potentially help to avoid ‘doomed’ main trials. They also
state that in many cases, pilot trials are performed in
order to generate data for sample size calculations in the
main study.
Prescott and Soeken [5] meanwhile, suggest five pilot
trial aims based on a review of then-current nursing re-
search text books including: a feasibility assessment; ad-
equacy of instrumentation and answering methodological
questions.
To address the aims of a pilot trial a sample size justi-
fication is required. Hertzog [6] highlights that there is
little published guidance on for a pilot trial sample size.
However, when applying for funding for a pilot trial, a
review panels would expect a justification for the
planned sample size. This justification could be based on
a number of methods:
 Hertzog [6] recommends the Julious and Patterson
[7] method of using confidence intervals for a given
precision constructed around the anticipated value
to set the sample size;
 Stallard [3] proposes that the sample size should be
approximately 0.03 times that the sample size
planned to be included in the definitive study;
 Browne [8] gives a general rule is to take a
minimum of 30 patients to estimate a parameter;
 Julious [9] recommends a minimum sample size of
12 per group as a rule of thumb and justifies this
based on rationale about feasibility and precision
about the mean and variance;
 Sim and Lewis [10] suggest a sample size of at least
50 per group.
Setting an appropriate sample size for any study is im-
portant. If a study is too large it may be judged to be un-
ethical as participants may be unnecessarily exposed to
risks and burdens [11]. There is the additional issue thatsetting the sample size too high may lead to a prevent-
able failure to reach the recruitment target [12]. While
Julious [9] highlights that a sample size that is too small
will have an imprecisely estimated variance, which could
impact on the design of a future definitive study.
This paper aims to build on the work of Lancaster
et al. [12] who reviewed pilot trials published from 2000
to 2001 in seven major journals and Arain et al. [2] who
revisited the same seven journals from 2007 to 2008 to
see if there had been any change in how pilot trials were
reported.
Arain et al. [2] concluded that pilot trials are poorly
reported and that the authors are often not explicit as to
the purpose of their pilot trial. They also found that
sample size calculations were only performed and
reported in 35% of the trials and that those identified
using the key word ‘pilot’ were more likely to have a
pre-study sample size calculation.
Using data from the United Kingdom Clinical Research
Network (UKCRN) Database we extend the work of
Lancaster et al. [12] and Arain et al. [2] by investigating
the sample size of pilot and feasibility trials for RCTs cur-
rently running in the United Kingdom (UK). The aim was
to investigate on-going sample sizes for pilot/ feasibility
trials in the UK. Although as discussed, there are defini-
tions of pilot and feasibility available, we recognise that in
reality the terms are often used interchangeably. However,
Arain et al. [2] found that there were some differences be-
tween the designs of studies labelled pilot and feasibility.
Therefore, in this investigation we will distinguish between
pilot and feasibility trials in the analysis. We will further
look at whether the sample sizes chosen varies between
the two study types (pilot or feasibility), as defined by the
principal investigator in their UKCRN Database entry.
The paper will also investigate if the sample size
chosen for the trial is influenced by factors such as how
the trial is funded or the type of endpoint.
The three research aims of the paper are:
1 To describe the sample sizes set for trials labelled
pilot versus feasibility
2 To describe the sample sizes set for trials with a
dichotomous compared to a continuous endpoint
3 To describe the sample sizes set in trials funded by
industry, public bodies or charities.
Methods
Trial identification
The UKCRN database, [http://public.ukcrn.org.uk/search/
(data last accessed, 20 March 2013)] [13] was used to
identify pilot and feasibility trials currently ongoing in the
UK. The database comprises of the National Institute for
Health Research (NIHR) portfolio in England, and the cor-
responding portfolios of Northern Ireland, Scotland and
Assessed for eligibility
n = 178 (feasibility)
n = 335 (pilot) 
Total = 513 
Excluded (n = 434)
Observational 
n = 46 (feasibility)
n = 129 (pilot)
Closed
n = 88 (feasibility)
n = 132 (pilot)
Non-randomised
n = 8 (feasibility)
n = 12 (pilot) 
Duplicates
n = 4 
Surveys
n = 2 (pilot)
Cluster trials 
n = 1 (pilot) 
n = 7 (feasibility) 
Eligible (n = 84) 
No data available
n = 1 (feasibility)
n = 4 (pilot)
Analysed 
n = 25 (feasibility)
n = 50 (pilot) 
n = 4 (pilot + feasibility)
Total = 79
Figure 1 Flow diagram showing the flow of trials through
the review.
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clinical research network (CRN), however, it is not com-
pulsory for researchers to register with the UKCRN [14].
The database is accessible by anyone online through the
URL listed above. The search was conducted on the 17th
May 2012 using the key words ‘Pilot’ or ‘Feasibility’ in the
title or research summary. These were the same key words
used by Lancaster et al. [12] and Arain et al. [2] and were
used here to maintain consistency with previous research.
The search results were exported to Excel and the
studies were sorted first by primary study design in
order to separate the interventional trials from the ob-
servational studies. They were then sorted by active sta-
tus: in order to separate the open from the closed trials.
The open interventional trials were then assessed against
the eligibility criteria as set out below. After the trials had
been assessed against the inclusion criteria the eligible tri-
als were exported into SPSS version 18.0 [15] for analysis.
Trials were eligible for further analysis if:
 They were randomised controlled trials;
 They were currently recruiting participants;
 They were classified as interventional;
 The participants were not healthy volunteers;
 They were not cluster randomised trials.
Trials were only included in the analysis if they were
open in order to get the most up to date picture of sample
sizes being used for pilot trials in the UK. Trials being
conducted on healthy volunteers were not included as
these are not usually efficacy studies. Cluster randomised
trials were excluded from further analysis as they tend to
require much larger target sample sizes (in terms of num-
bers of patients not clusters) than those trials which ran-
domise patients individually. Cluster randomised trials
also have different methodological issues and concerns
when undertaking a pilot trial – for example to estimate
the intra-class correlation (ICC).
Data extraction
Data on the target sample size and components of the
trials that might influence the target sample size such as,
type of end point, funder, number of treatment arms and
disease area were collected.
The information was extracted from the research sum-
mary of the UKCRN database when available. Forty-four of
the trials provided an International Standard Randomised
Controlled Trial Number [ISRCTN, http://isrctn.org/ (Date
last accessed 23rd March 2013)] these were then used to
conduct individual searches of the ISRCTN Register, when
information was missing.
To complement the search of the UKCRN database, an
Internet search was undertaken to find the trial or other
websites when information about the trial was missing fromthe UKCRN. Additional websites used included the US
clinicaltrials.gov and the website of the funder of the study.
After conducting all of these searches 62 (75%) of the tri-
als did not have complete information and so, in these
cases, the principal investigator or funder(s) were contacted
by email for the study protocol in question, in all cases re-
sponses were received.
Analysis plan
Medians and ranges were calculated overall for the dif-
ferent types of trial and then broken down by endpoint
and whether the trial was public or industry funded.
Results
The search of the UKCRN database yielded 178 studies
with the search term ‘feasibility’ and 335 studies with the
search term ‘pilot’. After eliminating duplicates, removing
any studies not meeting the inclusion criteria and studies
where no data were available, 83 trials went on to be
analysed. Studies with no data available, means that al-
though the trial was registered, no information regarding
the trial was listed or available from other sources. In these
cases (n = 5) the trial investigators were contacted how-
ever, none of these replied and the trials were assessed as
ineligible. Of those eligible, 26 had been labelled as a feasi-
bility by the investigators, 53 had been labelled a pilot trial
and 4 had received the label of both a pilot and a feasibil-
ity. Figure 1 shows the flow of trials through the review.
Trial characteristics
Table 1 summarises the characteristics of the trials that
met the inclusion criteria. The majority of the trials
Table 1 Trial characteristics of the studies included in the final analysis
Description of preliminary study
Pilot Feasibility Both Total
n (%) n (%) n (%) n (%)
Number of arms Two 39 78.0 25 100.0 4 100.0 68 86.1
Three 10 20.0 0 0.0 0 0.0 10 12.7
Four 1 2.0 0 0.0 0 0.0 1 1.3
Type of trial Health technology 34 68.0 23 92.0 3 75.0 60 75.9
Drug 16 32.0 2 8.0 1 25.0 19 24.1
Disease area Stroke 4 8.0 1 4.0 0 0.0 5 6.3
Mental health 11 22.0 6 24.0 1 25.0 18 22.8
Oncology 4 8.0 4 16.0 0 0.0 8 10.1
Respiratory 3 6.0 1 4.0 0 0.0 4 5.1
Oral & Gastrointestinal 3 6.0 2 8.0 0 0.0 5 6.3
Dementias 3 6.0 1 4.0 0 0.0 4 5.1
Cardiovascular 2 4.0 2 8.0 1 25.0 5 6.3
Primary care 5 10.0 2 8.0 0 0.0 7 8.9
Musculoskeletal 4 8.0 1 4.0 0 0.0 5 6.3
Other 11 22.0 5 20.0 2 50.0 18 22.8
Type of end point Dichotomous 15 30.0 12 48.0 4 100.0 31 39.2
Continuous 35 70.0 10 40.0 0 0.0 45 57.0
Time-to-event 0 0.0 1 4.0 0 0.0 1 1.3
Other 0 0.0 2 8.0 0 0.0 2 2.5
Funder Industry 11 22.0 1 4.0 1 25.0 13 16.5
Public 27 54.0 17 68.0 3 75.0 47 59.5
Charity 12 24.0 7 28.0 0 0.0 19 24.1
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treatment and one control treatment, whether that
control be active, a placebo or usual care. The majority
of the trials had either a continuous endpoint (n = 45,
57.0%) or a dichotomous endpoint (n = 31, 39.2%).
The most common disease areas for the trials were,
mental health (n = 18, 22.8%) oncology (n = 8, 10.1%)
and primary care (n = 7, 8.9%). Although there was a
large variety of clinical areas being investigated as shown
in Table 1. Approximately 75% of the trials were health
technology trials (n = 60) with drug trials making up
the remaining percentage (n = 19).
Most of the trials (n = 47, 59.5%) were publicly funded,
with the remaining trials being funded by either a char-
ity (n = 19, 24.1%) or industry (n = 13, 16.5%).
Sample size
The UKCRN database provided a target sample size for
each trial in their research summary. However, there
were no data available to explain why each target sample
size had been chosen.
In approximately 11% of cases (n = 9), the researchers
had recruited more patients to date than they initiallysaid would be required. These trials ranged from having
a sample size per arm of 15 to 100.
Data were first gathered on the target sample size per
arm for pilot and feasibility trials. Those trials labelled
pilot were found to have a smaller sample size per arm
(median of 30; range 8 to 114 participants) than those
labelled feasibility (median of 36; range 10 to 300 partici-
pants), these results and the inter-quartile ranges (IQR)
are shown in Table 2. Over all, the median sample size
per arm was found to be 30 (range 8 to 300).
Data on the median sample size were then analysed
according to funder. The results are shown in Table 2.
Publicly funded pilot trials have a median sample size of
36 (range 10 to 300 participants) and industry funded
pilot trials have a median sample size of 30 (range 8 to
100 participants).
The data were also analysed with regard to type of
endpoint used. The results are shown in Table 2. Those
studies with a dichotomous endpoint had a median sam-
ple size larger than those with a continuous endpoint.
Finally, the data were broken down by both funder
and endpoint. The results are shown in Table 3. Public
pilot trials with a continuous endpoint were on average
Table 2 Median sample size per arm according to type of
study, funder and endpoint
Sample size per arm
n Median (IQR) [Range]
Trial description Pilot 50 30 (20, 45) [8, 114]
Feasibility 25 36 (25, 50) [10, 300]
Both 4 49 (36, 61) [23, 72]
Type of endpoint Dichotomous 31 36 (25, 50) [10, 300]
Continuous 45 30 (20, 50) [8, 114]
Funder Industry 13 30 (16, 31) [8, 100]
Public 47 36 (25, 60) [10, 300]
Charity 19 30 (20, 45) [15, 52]
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endpoint (medians of 30 and 23 respectively). The same
applies to the public and industry funded pilot trials with
a dichotomous endpoint (medians of 36 and 25 respect-
ively). Feasibility trials with a dichotomous endpoint in
publicly funded trials are on average larger than the
equivalent continuous endpoint trials.
Discussion
Building on the work of Lancaster et al. [12] and Arain
et al. [2] the trials analysed in this paper were trials cur-
rently running in the United Kingdom on the date the
search was conducted, giving us a wide range of infor-
mation regarding target sample sizes. All the trials that
met the inclusion criteria stated a target sample size for
their trial within their research summary. Although it is
not a requirement in none of the summaries was there a
justification given for the target sample size given.
Moore et al. [16] highlighted that it is not unusual for
study proposal reviewers to come across a statement
such as “No sample size justification is needed because
of the pilot nature of the proposed study”, but they state
that pilot trials are not exempt from needing a clear ra-
tionale for the number of patients to be included.Table 3 Median sample sizes per arm of pilot and
feasibility studies by endpoint and funder
Sample size per arm
n Median (IQR) [Range]
Pilot Industry Dichotomous 5 25 (25, 30) [10, 90]
Continuous 6 23 (15, 31) [8, 100]
Public Dichotomous 6 36 (30, 42) [20, 60]
Continuous 21 30 (20, 60) [15, 114]
Feasibility Industry Dichotomous 0 . .
Continuous 1 30 .
Public Dichotomous 9 50 (30, 70) [25, 300]
Continuous 6 43 (15, 60) [10, 60]However, Arain et al. [2] discovered that only a small
proportion of published pilot trials report pre-study
sample size calculations as most journal editors state
that it is not mandatory criterion for publication.
An investigation of the expected benefits, risks and
costs of the study is required to justify a target sample
size [16]. However, it is important to remember that a
target sample size for a pilot or feasibility study is only a
preliminary figure and has a great degree of uncertainty.
For example, the researchers may find that more partici-
pants drop out than first presumed. We have shown that
target sample sizes vary for preliminary trials. Consider-
ing the median sample sizes for pilot and feasibility trials
our data shows that on average feasibility studies are lar-
ger than pilot trials: although there is wide variability in
the sample sizes across all types of trial. The median
sample size per arm across all the types of study was 30.
With regards to target sample size according to funder,
a study of registered drug trials by Bourgeois et al. [17],
across a wide variety of types of trial, found that those
funded by industry were more likely to have a larger
sample size than those funded by government sources.
However, our analysis indicated that publicly funded
pilot trials were larger than industry funded pilot trials.
Campbell et al. [18] describe sample size calculations
for studies that have dichotomous, ordered categorical
and continuous endpoints. They state that approximately
30% fewer patients are required for a study with a con-
tinuous endpoint – in our research we found that for a
dichotomous endpoint compared to a continuous the
median sample size was 20% bigger.
Looking at the differences in sample size according to
type of primary endpoint and funder we found that there
is a larger difference in sample size between trials with a
dichotomous endpoint compared to a continuous end-
point for publicly funded trials compared to industry
funded trials.
It would be beneficial to follow-up the pilot and feasi-
bility trials discussed in this paper to see how many go
on to be published – to see if there is a difference be-
tween those published and not published. Another pos-
sible extension would be to investigate the different
sample sizes of trials dependent on whether the primary
endpoint of the trial is based on efficacy or feasibility.
The limitations of this study include the fact that only
one trial registry was used to collect the data meaning
that it is possible that eligible trials that were not regis-
tered with the UKCRN are missing from the analysis. If
these trials differ in some way from the trials listed on
the UKCRN then this could affect the conclusions made.
The database used only trials being carried out in the
UK, which could also affect the generalisability of the re-
sults. The search was only carried out by one reviewer
and was not repeated to check for accuracy. In addition,
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therefore, some trials labelled for example, exploratory
or preliminary could have been missed during data ex-
traction. However, these search terms were used to
maintain consistency with previous research [2,12].
Conclusion
All trials should have a sample size justification. Not all
trials however need to have a sample size calculation. For
feasibility and pilot trials, while a sample size justification
is important, a formal calculation may not be appropriate.
In our study we found that the median pilot study sample
sizes for two arm trials were 36 and 30 per arm respect-
fully for dichotomous and continuous endpoints.
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